Close menu




MORPHOSYS AG O.N.

Photo credits: pixabay.com

Commented by André Will-Laudien on July 29th, 2021 | 13:56 CEST

Alibaba, Memiontec, MorphoSys - Now the rally after the sell-off!

  • Investments

The regulator's pressure is getting bigger and bigger. China has tightened the thumbscrews on technology giants and especially their online education companies - triggering a stock market quake on its own stock market. In some cases, well-known tech stocks lost double digits, even though the affected areas only affect fractions of annual sales. Government regulation of the USD 100 billion-plus education market is likely to weaken confidence in China's stock markets for the long term. And the fact that China's trade relations with the US have also reached a low point does not make things any better. Are there still opportunities?

Read

Commented by Stefan Feulner on July 28th, 2021 | 13:42 CEST

Commerzbank, Aztec Minerals, MorphoSys - Save yourself!

  • Commodities

The fear of rapidly rising interest rates was taken away from investors at the past meetings of the central banks. In addition to the ECB's change in monetary policy strategy, where the inflation target of "below or close to 2%" was set aside, the Federal Reserve is blithely continuing its money printing. Despite a 5.4% increase in prices in June, US monetary watchdogs continue to focus on a growing economy and a robust labor market and continue to hold off on a monetary policy response. These hesitant measures put financial stability at risk - the best conditions for investment in precious metals.

Read

Commented by Stefan Feulner on July 27th, 2021 | 13:01 CEST

BioNTech, XPhyto Therapeutics, MorphoSys - Here we go again

  • Biotechnology

The numbers of new SARS-CoV-2 infections in Germany are rising again, albeit still at a relatively low level. Due to the spread of the Delta variant, Health Minister Jens Spahn warns of incidences beyond the 800 mark as early as this fall. In addition to masking and spacing, the issues surrounding vaccines against the various mutations and regular, reliable testing are returning to the front pages of the news pages.

Read

Commented by Carsten Mainitz on June 30th, 2021 | 12:59 CEST

CureVac, Cardiol Therapeutics, MorphoSys - Here it is going powerfully upwards!

  • Biotechnology

Biotech stocks offer investors not only an exciting but also a very profitable investment environment. But the sector is also attractive for traders due to its high volatility. CureVac took a beating recently as the efficacy of its Corona vaccine disappointed. The price of MorphoSys falls despite good news and positive analyst comments. The Canadian Cardiol Therapeutics could be on the verge of a revaluation. Where can the most significant gains be made in the short term?

Read

Commented by Carsten Mainitz on June 22nd, 2021 | 12:36 CEST

MorphoSys, Defence Therapeutics, Formycon - Biotechnology shares with great potential

  • Biotechnology

In the wake of the corona pandemic, companies such as BioNTech, Pfizer and Moderna demonstrated how quickly and safely vaccines can be developed and mass-produced using innovative biotechnological processes. Biotech stocks have risen in favor again, even outside Covid-19. However, some stocks lag behind the price targets forecast by experts, while others are slowly moving (again) in the right direction. We look at three stocks that offer excellent opportunities at the current price level.

Read

Commented by Carsten Mainitz on June 18th, 2021 | 15:10 CEST

MorphoSys, Biogen, Sierra Growth - What is next?

  • Investments

Pharmaceutical stocks are a bit like that: Giants like Johnson & Johnson or Novartis have an extensive product portfolio and can cushion failures of individual products quite well. It is often a matter of life and death for smaller, specialized companies with every development. Just yesterday, this could be observed in the CureVac share after its Corona vaccine candidate only achieved an efficacy of 47% in the clinical 2b/3 phase. Within a very short time, it disintegrated the stock price. Meanwhile, biotech pioneer Biogen surprised with an unjustified share price rally, which, however, could come to an abrupt end after a new setback. The situation is different for MorphoSys. Its planned acquisition of Constellation Pharmaceuticals initially weighed heavily on the share price, but it holds exciting potential. And the Canadian mining Company Sierra Growth is operating in a completely different environment; however, it has a top opportunity to offer in the current inflationary environment and should not go unmentioned.

Read

Commented by André Will-Laudien on June 11th, 2021 | 08:26 CEST

Varta, MorphoSys, Theta Gold Mines - Strong tailwind from politics!

  • Gold

As an entrepreneur, it is a particular challenge today to find business models that will come into political focus in the near future. We had this at the turn of the millennium in mobile communications when licenses were sold for future generations. In the meantime, there have been important changes in infrastructure and energy policy - one man's joy is another man's sorrow - and now the government is considering the expansion in the direction of climate protection, only approving new houses with mandatory solar installations. Another major intervention, but certainly in the right direction!

Read

Commented by Armin Schulz on June 9th, 2021 | 10:20 CEST

windeln.de, NSJ Gold, MorphoSys - High flyers of today and tomorrow

  • Gold

These are crazy times on the stock market and it is not easy to find the next high flyer. At the moment, even in Germany, there are gambler stocks, such as Adler Modemärkte. Markets are at their all-time highs and even if many cannot comprehend it, I guess you have to get used to it. Money that would otherwise have gone into government bonds flows into the equity markets, bringing a dividend yield instead of interest. Today we present three possible high flyers, whereby windeln.de has probably already gone too far.

Read

Commented by Stefan Feulner on June 7th, 2021 | 09:37 CEST

Bayer, Defence Therapeutics, MorphoSys - A paradigm shift in biotechnology

  • Biotechnology

The search for a vaccine against the Coronavirus brought biotechnology back into the focus of investors last year. Companies such as BioNTech or CureVac were able to multiply in this regard. In 2020, the biotech sector in Germany raised a record sum of EUR 3 billion, and the trend is rising sharply. The fight against incurable diseases and the development of important innovations such as vaccines, cancer therapies, or sustainable products lift the segment into higher realms and offer attractive investment opportunities.

Read

Commented by Stefan Feulner on May 10th, 2021 | 09:14 CEST

CureVac, Cardiol, MorphoSys - Huge sensation in the fight against Corona!

  • Biotechnology

The biotechnology sector gained tremendous attention since the start of the Corona pandemic. With vaccine makers such as BioNTech or Moderna, investors have achieved returns beyond 1000% since the end of 2019. Currently, drug research against Sars-CoV-2 is in full swing. More effective and safe drugs along with vaccination and testing strategies are critical to managing the pandemic. For investors, this meant a second chance at the next tenbagger.

Read